Nevertheless, with clinical trials in the context of virus-induced pneumonia and systemic inflammation already revealing beneficial safety profiles (63, 80, 81), therapeutic interventions disrupting TNFSF14-initiated intercellular pathways to preserve TR-AM function appear to be promising approaches for improving host defense in the context of IAV pneumonia. This evidence concerns the gene TNFSF14 and susceptibility to pneumonia measurement.